<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749333</url>
  </required_header>
  <id_info>
    <org_study_id>D1320C00001</org_study_id>
    <nct_id>NCT00749333</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of AZD8566.</brief_title>
  <official_title>A Phase I, Randomised, Double Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Oral Doses of AZD8566 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how well tolerated and safe AZD8566 is at different
      dose levels. This study will also determine how AZD8566 is distributed around the body and
      how it leaves the body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile: concentration of AZD8566 in blood</measure>
    <time_frame>Samples taken during Visit 2 (residential period) at up to 16 defined timepoints pre-dose and post- dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of AZD8566 by assessment of vital signs, laboratory variables, ECG and adverse events</measure>
    <time_frame>Assessments taken at Visit 1 (enrolment), defined timepoints pre-dose and post-dose during Visit 2 (residential period) and at Visit 3 (follow up). Volunteers will be monitored throughout the study from Visit 1 to Visit 3 for adverse events.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile: concentration of AZD8566 in urine</measure>
    <time_frame>Samples collected over 48 hours from pre-dose to 48 hours post-dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8566</intervention_name>
    <description>solution. Specific dose will be selected by the safety review committee</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single 10ml oral solution.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent.

          -  Clinically normal physical findings and laboratory values as judged by the
             investigator with normal ECG

          -  Females who are permanently or surgically sterile or postmenopausal.

        Exclusion Criteria:

          -  Intake of medicine (except Hormone Replacement Therapy or occasional paracetamol)
             within 3 weeks before first administration of study drug

          -  History of any convulsions or seizures

          -  History of infection or at risk of infection due to recent surgery or trauma

          -  History or presence of conditions known to interfere with the absorption,
             distribution, metabolism and excretion of the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Fahy, MD,MA, MBBS (Hons)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology Unit, Queen's Medical Centre, Nottingham, NG7 2UH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <last_update_submitted>April 29, 2009</last_update_submitted>
  <last_update_submitted_qc>April 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Harsukh Parmar, Medical Science Director, Respiratory and Inflammation Emerging Product Team</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>AZD8566</keyword>
  <keyword>study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

